Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the role of the immune system in response to lapatinib is not fully understood...

Descripción completa

Detalles Bibliográficos
Autores principales: Chumsri, Saranya, Li, Zhuo, Serie, Daniel J., Norton, Nadine, Mashadi-Hossein, Afshin, Tenner, Kathleen, Brauer, Heather Ann, Warren, Sarah, Danaher, Patrick, Colon-Otero, Gerardo, Partridge, Ann H., Carey, Lisa A., Hilbers, Florentine, Van Dooren, Veerle, Holmes, Eileen, Di Cosimo, Serena, Werner, Olena, Huober, Jens Bodo, Dueck, Amylou C., Sotiriou, Christos, Saura, Cristina, Moreno-Aspitia, Alvaro, Knutson, Keith L., Perez, Edith A., Thompson, E. Aubrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130150/
https://www.ncbi.nlm.nih.gov/pubmed/35610260
http://dx.doi.org/10.1038/s41523-022-00430-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130150/
https://www.ncbi.nlm.nih.gov/pubmed/35610260
http://dx.doi.org/10.1038/s41523-022-00430-0

Ejemplares similares